Clinical Trials Browser

Phase 2 × Recurrent Squamous Cell Lung Carcinoma × Clear all

NCT03373760 2023-06-09

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Phase 2 Completed

67 enrolled 17 charts

Recurrent Squamous Cell Lung Carcinoma

NCT03574753 2021-10-18

Lung-MAP S1400K: c-MET Positive

Phase 2 Completed

28 enrolled 18 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02785913 2020-10-23

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Phase 2 Completed

31 enrolled 14 charts

Recurrent Squamous Cell Lung Carcinoma